Celltrion to Buy Eli Lilly's New Jersey Manufacturing Plant to Limit US Tariff Impact
MT Newswires Live
Sep 23, 2025
Celltrion (KRX:068270) agreed to acquire Eli Lilly's manufacturing facility in New Jersey for 700 billion won, which included operating funds, to cushion the impact from US tariffs, the South Korean biopharmaceutical company said Tuesday.
The manufacturing facilities comprise four buildings on a site spread across 45,000 pyeong.
Celltrion expects immediate operational readiness, reduced contract manufacturing organization (CMO) and logistics costs, and early return on investment through existing CMO contracts and full employment succession.
The acquisition is scheduled for completion by end-2025, pending US regulatory approvals.
Shares of Celltrion jumped nearly 9% at market close.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.